Mobocertinib: Mechanism of action, clinical, and translational science
Abstract Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations represent ~6%-12% of all EGFR‐mutated non‐small cell lung cancer (NSCLC) cases. First‐, second‐, and third‐generation tyrosine kinase inhibitors (TKIs) have limited clinical activity against EGFR ex20ins mutations...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Bog |
| Udgivet: |
Wiley,
2024-03-01T00:00:00Z.
|
| Fag: | |
| Online adgang: | Connect to this object online. |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|
Internet
Connect to this object online.3rd Floor Main Library
| Klassifikationsnummer: |
A1234.567 |
|---|---|
| Kopi 1 | Tilgængelig |